Circulating immune complexes in sera from patients receiving procainamide. |
| |
| Authors: | M Becker A Klajman T Moalem A Yaretzky S Ben-Efraim |
| |
| Affiliation: | 1. Campus Box 94, University of Northern Colorado, Greeley, CO 80639, United States;2. California Pacific Medical Center, 3700 California Street, San Francisco, CA 94118, United States |
| |
| Abstract: | Sera from patients receiving procainamide (PrA) therapy were investigated for their ability to inhibit an antibody-dependent cell-mediated cytotoxicity system (ADCC). Before the start of therapy 1 out of 20 sera from patients were inhibitory. Two months following the onset of therapy, 21 out of 29 sera (72%) inhibited ADCC. Sera from 13 out of 29 (44%) patients receiving PrA for periods greater than 6 months still displayed inhibitory factors. The inhibitory factors were found by sucrose-gradient ultracentrifugation to be located mainly in fractions 7 S to 19 S. Adsorption of sera with anti-human IgG linked to Sepharose removed inhibitory factors whereas similar treatment with anti-human IgM Sepharose did not, indicating that IgG was present in the inhibitory material. These results are consistent with the hypothesis that PrA induces IgG-containing immune complexes. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
